Daily Pharma News - 24 October 2026

Diabetes care dominated today's pharma headlines, with generic semaglutide moves in India, regulatory caution on oral GLP-1 tablets, and a landmark once-weekly insulin approval in the US. Enforcement news from Telangana and GMP scrutiny at Gland Pharma rounded out a regulator-heavy day. Here is what pharmacy students need to know.

Dr Reddy's Launches Obeda Pro and Obeda Plus After Original Obeda Supply Disruption

Dr Reddy's Laboratories has launched two new generic semaglutide injection brands, Obeda Pro and Obeda Plus, as it continues to work around a supply disruption of its original Obeda brand, according to Reuters. Obeda supplies were halted in July 2026 after an impurity was detected in the active pharmaceutical ingredient, a reminder of how a single API quality deviation can take an entire brand off pharmacy shelves. The two new brands are manufactured at a different partner facility, showing how companies derisk supply chains by qualifying alternate manufacturing sites.

For Indian pharmacy students, this story is a practical case study in two directions. First, it shows the business logic of brand segmentation in the generic GLP-1 race that has exploded in India since semaglutide patents loosened. Second, it underscores pharmacovigilance fundamentals: impurity-led market action is exactly the kind of quality event that D.Pharm and B.Pharm syllabi cover under pharmaceutical analysis and regulatory affairs. CDSCO's concurrent scrutiny of oral semaglutide products (see below) shows Indian regulators are watching this therapeutic class closely from every angle.

CDSCO Seeks More Data From Novo Nordisk for Oral Wegovy Tablets in India

The Central Drugs Standard Control Organisation's endocrinology expert committee has declined to clear Novo Nordisk's proposal to market oral semaglutide tablets in strengths of 1.5 to 25 mg under the Wegovy brand, asking the company for India-specific bioequivalence data first, The South First reports. Oral semaglutide pairs the GLP-1 molecule with an absorption enhancer (SNAC technology), and its bioavailability is notoriously sensitive to dosing conditions - a food-effect variable that regulators scrutinise before approving new markets.

Separately, Torrent Pharmaceuticals received regulatory clearance to begin a Phase-III clinical trial of semaglutide for diabetes, signalling that Indian companies are racing to build their own evidence packages in the GLP-1 space. For pharmacy students, the CDSCO decision is a textbook illustration of bioequivalence and biowaivers: regulators may accept foreign data for some products but demand local data when absorption is formulation-sensitive. Watch this space - once oral GLP-1 tablets reach Indian pharmacies, counselling points around administration timing and food interactions will become a major patient-care topic.

TG SAFE Suspends 106 Medical Shop Licences in Hyderabad Crackdown on Habit-Forming Drug Sales

Telangana's drug enforcement wing TG SAFE suspended the licences of 106 medical shops in Hyderabad's CURE region, cancelled one licence and issued warnings to three more, following an enforcement drive on 6 October that uncovered illegal sale of habit-forming drugs, psychotropic substances and Schedule H and H1 medicines without prescriptions, The South First reports. Schedule H1 drugs - a category introduced in 2013 to curb antibiotic and psychotropic misuse - require strict prescription documentation and maintenance of dispensing records for three years.

This is directly relevant for pharmacy students and future community pharmacists: dispensing without a prescription is not a procedural slip but a licence-ending offence. The enforcement also covered psychotropic substances under the NDPS Act, where violations carry criminal liability, not just administrative action. For students preparing for pharmacist registration or the drug inspector cadre, cases like this are exactly what enforcement pharmacology looks like in practice - rulebooks on prescription verification, record-keeping, and controlled-substance storage are examined against real inspections.

USFDA Concludes Dundigal Inspection at Gland Pharma With Four Form 483 Observations

Gland Pharma disclosed on 23 October that the US Food and Drug Administration has concluded an unannounced 12-day current Good Manufacturing Practice (cGMP) inspection at its formulation facility in Dundigal, Hyderabad, issuing four Form 483 observations, according to Kalkine India. The company stated the observations are procedural in nature, are not repeated observations, and are not related to data integrity - three qualifications that investors and quality professionals read as a relatively benign outcome.

For pharmacy students, this is a live window into the global GMP ecosystem they study in pharmaceutical regulatory science. A Form 483 is issued when an FDA investigator observes conditions that may violate the Food, Drug, and Cosmetic Act; companies must respond within 15 business days with corrective and preventive action (CAPA) plans. Gland Pharma is a major injectables player, and Dundigal's outcome matters because sterile injectable facilities face the most stringent cGMP scrutiny. Students should note the language discipline in such disclosures - "procedural" versus "data integrity" - since the latter would have been a far more serious signal.

Russia Updates Cerebral Palsy Clinical Guidelines for First Time Since 2016

Russia's Health Ministry has issued updated clinical guidelines for cerebral palsy, the first revision in a decade. Key changes include an expansion of botulinum toxin A products approved for use in children from two to four, clarified tolperisone dosing regimens from age one, and expanded sections on dystonia, speech and cognitive disorders, GxP News reports. Botulinum toxin A is the cornerstone of spasticity management in paediatric cerebral palsy, used to reduce muscle tone and improve motor function alongside physiotherapy.

While Russian guidelines do not directly govern Indian practice, they are valuable comparative material for pharmacology and therapeutics students studying paediatric neurology. The expanded botulinum toxin list reflects a decade of accumulated evidence on efficacy and immunogenicity across brands - a good example of how clinical guidelines evolve with real-world data rather than theory alone. It also ties into a broader theme pharmacy students should track: regulators and guideline bodies worldwide are revisiting paediatric dosing frameworks, an area where pharmacokinetic differences from adults demand dedicated evidence.

FDA Approves Awiqli, First Once-Weekly Insulin for Children Aged 10+ With Type 2 Diabetes

The US FDA has granted approval to Novo Nordisk's insulin icodec, marketed as Awiqli, as an adjunct to diet and exercise for children aged 10 and older with type 2 diabetes, after a priority review. Awiqli is the first and only once-weekly basal insulin for this age group, cutting basal injections from seven per week to one - a significant adherence advantage for paediatric patients, where injection burden is a major driver of poor glycaemic control.

This approval completes the diabetes triad of today's news and connects directly to India's semaglutide story: the global diabetes pipeline is shifting toward long-acting, low-burden regimens across insulin and GLP-1 classes alike. Pharmacy students should understand the pharmacology behind insulin icodec's extended half-life (achieved through albumin binding and reduced receptor-mediated clearance) and its clinical implications - weekly dosing changes titration logic, missed-dose recovery, and hypoglycaemia risk windows compared with daily basal insulins. Given India's large and growing paediatric type 2 diabetes burden, once-weekly insulin could reshape diabetes counselling here too.

FDA Clears Subcutaneous Induction for AbbVie's Skyrizi in Crohn's Disease

The US FDA has approved an at-home subcutaneous induction regimen for risankizumab (Skyrizi) via an on-body injector for adults with moderately to severely active Crohn's disease. The approval was based on the AFFIRM Phase-3 trial, which showed superior clinical remission and endoscopic response at week 12 with the subcutaneous induction regimen. Skyrizi, an interleukin-23 p19 inhibitor, previously required intravenous induction in a clinical setting before maintenance dosing.

The shift from IV to subcutaneous induction is part of a wider trend in monoclonal antibody therapy - patient-administered delivery improving convenience and reducing infusion-centre load. For pharmacy students studying biologics and immunopharmacology, this approval highlights two learning points: the mechanism of IL-23 blockade in inflammatory bowel disease, and the device-drug combination dimension, since on-body injectors add a human-factors and patient-training layer that pharmacists will increasingly need to counsel on. Indian patients may see biosimilar risankizumab on a longer timeline, but the delivery-innovation trend will reach Indian biologic brands too.

Conclusion

Today's news threads together into one clear theme: chronic-disease therapy is being redesigned around the patient - weekly instead of daily dosing, oral instead of injectable GLP-1s, at-home instead of clinic-based biologic induction. But today's enforcement and inspection stories are the other half of the picture: TG SAFE's Hyderabad crackdown and the FDA's Dundigal inspection show that regulators are tightening oversight of both retail dispensing and manufacturing quality at the same pace. For pharmacy students, the lesson is to follow both tracks together - keep learning the new molecules and delivery technologies, but stay equally sharp on Schedule H/H1 compliance, GMP fundamentals, and bioequivalence principles, because that is where pharmacists make their professional mark.

References

← All daily news